NASDAQ:XTLB XTL Biopharmaceuticals Q2 2026 Earnings Results & Report $1.58 +0.10 (+6.42%) As of 10:28 AM Eastern This is a fair market value price provided by Massive. Learn more. XTL Biopharmaceuticals reported Q2 2026 earnings on November 18, 2026. The company reported EPS of -$0.05. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateNovember 18, 2026TimeAfter Market Closes XTL Biopharmaceuticals EPS ResultsActual EPS-$0.05Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AXTL Biopharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile XTL Biopharmaceuticals Q2 2026 Earnings FAQ Did XTL Biopharmaceuticals beat earnings estimates for Q2 2026? XTL Biopharmaceuticals (NASDAQ:XTLB) reported earnings of -$0.05 per share for Q2 2026. The report was announced on Wednesday, November 18, 2026. XTL Biopharmaceuticals Earnings HeadlinesXTL Biopharmaceuticals Ltd. Sponsored ADRJuly 8, 2026 | cnn.comXTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) After-HoursJuly 1, 2026 | nasdaq.comGet your evenings backThe Instant Scanner delivers the night's qualifying setups with exact buy prices and defined exits, in minutes. No hours of flipping through charts, no second-guessing patterns. It's built for traders who want the result without the ritual: a short list and your evening back. Black Friday price is $7 versus the regular $247. One payment covers a full year, with no re-bills.November 20 at 1:00 AM | Profits Run (Ad)XTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Establish Psychedelic Biotechnology PlatformJune 30, 2026 | quiverquant.comQXTL Completed the Acquisition of Psyga Bio Ltd.June 30, 2026 | globenewswire.comXTL Biopharmaceuticals Adjourns Extraordinary Shareholder Meeting to June 29, 2026June 23, 2026 | tipranks.comSee More XTL Biopharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like XTL Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XTL Biopharmaceuticals and other key companies, straight to your email. Email Address About XTL BiopharmaceuticalsXTL Biopharmaceuticals (NASDAQ:XTLB) is an Israel-based company listed on Nasdaq that has focused on developing and commercializing biopharmaceutical products. Its business strategy has also included acquiring and developing pharmaceutical and medical-device businesses. Historically, the company pursued drug candidates for autoimmune diseases. Its research included hCDR1, an investigational peptide studied for systemic lupus erythematosus. These programs reflect its earlier development work and should not necessarily be understood as products currently marketed by the company.View XTL Biopharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Airfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to RunGrand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItHome Depot Posts a Q3 Double Beat, But Is Its Rebound Built to Last? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.